<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02961647</url>
  </required_header>
  <id_info>
    <org_study_id>A5130</org_study_id>
    <nct_id>NCT02961647</nct_id>
  </id_info>
  <brief_title>Hemodynamic Stress Test in Severe Mitral Regurgitation (HEMI)</brief_title>
  <acronym>HEMI</acronym>
  <official_title>Invasive Hemodynamic Stress Test in Symptomatic and Asymptomatic Mitral Regurgitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The preferred treatment of organic mitral regurgitation (MR) is mitral valve repair.
      Optimally this should be timed so late that it commensurate with the risk of surgery and
      before irreversibly damage of the heart and pulmonary vessels. The aim is to obtain an
      understanding of the differences between the symptomatic and asymptomatic patient.

      The study will test

      A: Symptomatic organic MR is characterized by higher filling pressure, and higher stroke work
      during physical strain compared with asymptomatic MR.

      B: The extent of myocardial fibrosis is associated with filling pressure and cardiac index 1
      year after mitral valve repair.

      C: Filling pressure can be estimated non-invasively by echocardiography. To test this 40
      patients with asymptomatic MR and 40 symptomatic will undergo a stress echocardiography with
      simultaneous echocardiography and invasive measurement of central hemodynamics. In addition a
      pulmonary function test and cardiac MRI will be performed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background

      Degenerative mitral valve disease is the most common cause of organic mitral regurgitation in
      the Western World. The preferred treatment of organic mitral regurgitation is mitral valve
      repair. Optimally this should be timed so late that it commensurate with the risk of surgery
      and before irreversibly damage of the heart and pulmonary vessels. According to the current
      guidelines mitral valve surgery is indicated in symptomatic patients with severe MR or in
      presence of known risk factors. The optimal timing of surgery is still controversial in the
      asymptomatic patients without risk factors.

      The overall aim of the present study is to obtain a better understanding of the central
      hemodynamics at rest and during physical exercise in both symptomatic and asymptomatic
      patients with organic mitral regurgitation, the relation to neurohormonal activation and
      myocardial fibrosis, and to identify noninvasive echocardiographic measures suitable for
      estimation of this.

      A epidemiologic sub-study aims to asses whether MR is associated with inherence, as familial
      clustering of mitral regurgitation earlier has been suggested based only mainly on small
      observational studies, and case reports.

      Methods

      The study will test

      A: Symptomatic organic MR is characterized by higher filling pressure, and higher stroke work
      during physical strain compared with asymptomatic MR.

      B: The extent of myocardial fibrosis is associated with filling pressure and cardiac index 1
      year after mitral valve repair.

      C: Filling pressure can be estimated non-invasively by echocardiography.

      To test this 40 patients with asymptomatic MR and 40 patients with symptomatic MR will
      undergo a stress echocardiography with simultaneous echocardiography and invasive measurement
      of central hemodynamics. In symptomatic patients that undergo surgery, the examination will
      be repeated 1 year after the surgical mitral valve repair.

      In addition pulmonary function test, maximal oxygen consumption test and cardiac MRI will be
      performed.

      The Danish Twin Registry and The Danish National Patient Registry will be used to identify
      twins with MR. The hypothesis is that the concordance rate is higher in monozygotic twins
      compared to dizygotic twins.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary artery wedge pressure</measure>
    <time_frame>One year after mitral valve replacement</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extent of myocardial fibrosis</measure>
    <time_frame>One year after mitral valve replacement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal oxygen consumption</measure>
    <time_frame>One year after mitral valve replacement</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Mitral Valve Regurgitation</condition>
  <arm_group>
    <arm_group_label>Asymptomatic patients</arm_group_label>
    <description>Patients with asymptomatic severe mitral valve regurgitation not undergoing surgical repair of the valve.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symptomatic patients</arm_group_label>
    <description>Patients with symptomatic severe mitral valve regurgitation undergoing surgical repair of the valve.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mitral valve repair</intervention_name>
    <description>The intervention is NOT related to the study design. It is a description of patients undergoing surgery vs. not undergoing surgery and this decision is made according to current guidelines (patients are not randomized).</description>
    <arm_group_label>Symptomatic patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and tissue samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        In the research project the investigators will examine 80 patients with severe MR, of which
        40 do not experience symptoms.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Organic mitral valve regurgitation with effective regurgitation orifice (ERO)&gt;0.3 cm2

          -  Age &gt; 18 years

          -  Left ventricular ejection fraction (LVEF) &gt; 60% assessed by echocardiography

          -  Signed informed consent

        Exclusion Criteria:

          -  Poor echocardiographic window

          -  Inability to perform bicycle exercise testing

          -  Ischemic or functional (secondary) mitral valve regurgitation

          -  Chronic atrial fibrillation/flutter

          -  Hemodynamic significant aortic valve disease assessed by echocardiography.

          -  Treatment with oral anticoagulants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob Møller, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacob Møller, Professor</last_name>
    <email>jacob.moeller1@rsyd.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <state>Odense C</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rine Bakkestrøm, MD</last_name>
      <phone>0045 31164004</phone>
      <email>rine.bakkestroem@rsyd.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>https://open.rsyd.dk/OpenProjects/da/openProject.jsp?openNo=226</url>
  </link>
  <reference>
    <citation>Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Iung B, Lancellotti P, Pierard L, Price S, Schäfers HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012 Oct;33(19):2451-96. doi: 10.1093/eurheartj/ehs109. Epub 2012 Aug 24.</citation>
    <PMID>22922415</PMID>
  </reference>
  <reference>
    <citation>Bonow RO. Chronic mitral regurgitation and aortic regurgitation: have indications for surgery changed? J Am Coll Cardiol. 2013 Feb 19;61(7):693-701. doi: 10.1016/j.jacc.2012.08.1025. Epub 2012 Dec 19. Review.</citation>
    <PMID>23265342</PMID>
  </reference>
  <reference>
    <citation>Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, Detaint D, Capps M, Nkomo V, Scott C, Schaff HV, Tajik AJ. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med. 2005 Mar 3;352(9):875-83.</citation>
    <PMID>15745978</PMID>
  </reference>
  <reference>
    <citation>Suri RM, Vanoverschelde JL, Grigioni F, Schaff HV, Tribouilloy C, Avierinos JF, Barbieri A, Pasquet A, Huebner M, Rusinaru D, Russo A, Michelena HI, Enriquez-Sarano M. Association between early surgical intervention vs watchful waiting and outcomes for mitral regurgitation due to flail mitral valve leaflets. JAMA. 2013 Aug 14;310(6):609-16. doi: 10.1001/jama.2013.8643.</citation>
    <PMID>23942679</PMID>
  </reference>
  <reference>
    <citation>Naji P, Griffin BP, Asfahan F, Barr T, Rodriguez LL, Grimm R, Agarwal S, Stewart WJ, Mihaljevic T, Gillinov AM, Desai MY. Predictors of long-term outcomes in patients with significant myxomatous mitral regurgitation undergoing exercise echocardiography. Circulation. 2014 Mar 25;129(12):1310-9. doi: 10.1161/CIRCULATIONAHA.113.005287. Epub 2014 Jan 6.</citation>
    <PMID>24396041</PMID>
  </reference>
  <reference>
    <citation>Magne J, Mahjoub H, Pibarot P, Pirlet C, Pierard LA, Lancellotti P. Prognostic importance of exercise brain natriuretic peptide in asymptomatic degenerative mitral regurgitation. Eur J Heart Fail. 2012 Nov;14(11):1293-302. doi: 10.1093/eurjhf/hfs114. Epub 2012 Jul 10.</citation>
    <PMID>22782970</PMID>
  </reference>
  <reference>
    <citation>Ersbøll M, Valeur N, Mogensen UM, Andersen MJ, Møller JE, Velazquez EJ, Hassager C, Søgaard P, Køber L. Prediction of all-cause mortality and heart failure admissions from global left ventricular longitudinal strain in patients with acute myocardial infarction and preserved left ventricular ejection fraction. J Am Coll Cardiol. 2013 Jun 11;61(23):2365-73. doi: 10.1016/j.jacc.2013.02.061. Epub 2013 Apr 3.</citation>
    <PMID>23563128</PMID>
  </reference>
  <reference>
    <citation>Witkowski TG, Thomas JD, Debonnaire PJ, Delgado V, Hoke U, Ewe SH, Versteegh MI, Holman ER, Schalij MJ, Bax JJ, Klautz RJ, Marsan NA. Global longitudinal strain predicts left ventricular dysfunction after mitral valve repair. Eur Heart J Cardiovasc Imaging. 2013 Jan;14(1):69-76. doi: 10.1093/ehjci/jes155. Epub 2012 Jul 29.</citation>
    <PMID>22848021</PMID>
  </reference>
  <reference>
    <citation>Dalsgaard M, Kjaergaard J, Pecini R, Iversen KK, Køber L, Moller JE, Grande P, Clemmensen P, Hassager C. Left ventricular filling pressure estimation at rest and during exercise in patients with severe aortic valve stenosis: comparison of echocardiographic and invasive measurements. J Am Soc Echocardiogr. 2009 Apr;22(4):343-9. doi: 10.1016/j.echo.2009.01.007. Epub 2009 Mar 9.</citation>
    <PMID>19269785</PMID>
  </reference>
  <reference>
    <citation>Andersen MJ, Ersbøll M, Axelsson A, Gustafsson F, Hassager C, Køber L, Borlaug BA, Boesgaard S, Skovgaard LT, Møller JE. Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) trial. Circulation. 2013 Mar 19;127(11):1200-8. doi: 10.1161/CIRCULATIONAHA.112.000056. Epub 2013 Feb 13.</citation>
    <PMID>23406672</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2016</study_first_submitted>
  <study_first_submitted_qc>November 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Rine Bakkestrøm</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Hemodynamic stress test</keyword>
  <keyword>Surgical intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

